MA41557A - Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2 - Google Patents

Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2

Info

Publication number
MA41557A
MA41557A MA041557A MA41557A MA41557A MA 41557 A MA41557 A MA 41557A MA 041557 A MA041557 A MA 041557A MA 41557 A MA41557 A MA 41557A MA 41557 A MA41557 A MA 41557A
Authority
MA
Morocco
Prior art keywords
dimethoxyphenyl
inhibitors
vesicular monoamine
monoamine carrier
carrier
Prior art date
Application number
MA041557A
Other languages
English (en)
French (fr)
Inventor
Chengzhi Zhang
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of MA41557A publication Critical patent/MA41557A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001Acyclic or carbocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
MA041557A 2015-02-18 2016-02-16 Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2 MA41557A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562117654P 2015-02-18 2015-02-18

Publications (1)

Publication Number Publication Date
MA41557A true MA41557A (fr) 2017-12-26

Family

ID=56692737

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041557A MA41557A (fr) 2015-02-18 2016-02-16 Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2

Country Status (12)

Country Link
US (1) US10722479B2 (enExample)
EP (1) EP3258926A4 (enExample)
JP (1) JP2018507210A (enExample)
AR (1) AR103728A1 (enExample)
BR (1) BR112017017673A2 (enExample)
CA (1) CA2976229A1 (enExample)
EA (1) EA201791839A1 (enExample)
IL (1) IL253901A0 (enExample)
MA (1) MA41557A (enExample)
MX (1) MX2017010567A (enExample)
TW (1) TW201630871A (enExample)
WO (1) WO2016133989A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
JP7766623B2 (ja) 2020-05-19 2025-11-10 サイビン アイアールエル リミテッド 重水素化トリプタミン誘導体および使用方法
WO2026050236A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA852843B (en) 1984-05-15 1985-11-27 Warner Lambert Co Bevantolol preparation
BRPI0711221A2 (pt) * 2006-05-26 2012-03-13 Auspex Pharmaceuticals, Inc Composto, composição farmcêutica, método para o tratamento, prevenção ou melhora de um ou mais sintomas de doença mediada por receptor adrenérgico beta, método para tratar, prevenir ou melhorar um o mais sintomas de uma doença selecionada do grupo consistindo em uma desordem de ansiedade social, uma desordem de ansiedade, hipertirodismo, tremor, glaucoma, hipertensão, enxerto de desvio de artéria coronária, angina estável crônica, arritmia atrial , enxaqueca , varizes, esofagicas sangrando, estenose subaórtica hipertrófica, ataque cardíaco , infarto pós miocárdio, função ventricular esquerda diminuída após infarto do miocárdio recente e qualquer desordem melhorada por modulares do receptor adrenérgico beta e metodo para modular atividade de receptor adrenérgico beta
WO2008122010A1 (en) 2007-04-02 2008-10-09 Concert Pharmaceuticals, Inc. Pharmaceutical calcimimetics
US20100009950A1 (en) * 2008-06-30 2010-01-14 Auspex Pharmaceuticals, Inc. Substituted ethanolamines
EP3345905B1 (en) * 2008-09-18 2021-09-01 Auspex Pharmaceuticals, Inc. Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
US20100143287A1 (en) 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Trifluoromethylphenyl modulators of calcium-sensing receptor
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
EP2897615A4 (en) 2012-09-18 2016-04-27 Auspex Pharmaceuticals Inc PHARMACOKINETIC FORMULATIONS OF DEUTERATED BENZOCHINOL INHIBITORS OF THE VESICLE MONOAMINE TRANSPORTER 2
BR112015031835B1 (pt) 2013-06-19 2022-12-13 Som Innovation Biotech, S.L Usos de agentes terapêuticos, de uma combinação dos referidos agentes com um agente terapêutico adicional, e de uma composição farmacêutica para fabricação de medicamento para a profilaxia e/ou tratamento de distúrbios do movimento hipercinético

Also Published As

Publication number Publication date
EP3258926A1 (en) 2017-12-27
AR103728A1 (es) 2017-05-31
TW201630871A (zh) 2016-09-01
JP2018507210A (ja) 2018-03-15
MX2017010567A (es) 2018-03-16
IL253901A0 (en) 2017-10-31
CA2976229A1 (en) 2016-08-25
EA201791839A1 (ru) 2018-02-28
BR112017017673A2 (pt) 2018-07-17
WO2016133989A1 (en) 2016-08-25
US20180036260A1 (en) 2018-02-08
US10722479B2 (en) 2020-07-28
EP3258926A4 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
SI3494115T1 (sl) Derivati N-(fenilsulfonil)benzamida kot BCL-2 inhibitorji
ZA201906875B (en) Jak1 selective inhibitors
DK3672976T3 (da) Bcl-2-hæmmere
DK3328849T5 (da) 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamat-derivater og 1,1,1-trifluor-4-hydroxybutan-2-yl-carbamat-derivater som magl-inhibitorer
ME03580B (me) Ciklopropilamini kao lsd1 inhibitori
DK3298002T3 (da) Heterocykliske amider som kinasehæmmere
DK3105218T3 (da) Cyclopropylaminer som lsd1-inhibitorer
EP3099299A4 (en) Benzoquinoline inhibitors of vesicular monoamine transporter 2
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
HUE058120T2 (hu) Új JAK1-szelektív inhibitorok és alkalmazásuk
CL2016002638A1 (es) Nuevos inhibidores de la nitrificación
SI3240767T1 (sl) Mikroenkapsulirani sestavki zaviralca nitrifikacije
ZA201704116B (en) 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine compound inhibitors of beta-secretase
DK3137437T3 (da) Mikroindkapslet nitrifikationsinhibitorsammensætning
SMT202000653T1 (it) Nuovi inibitori di callicreina 7
MA41557A (fr) Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2
ZA201803212B (en) Gelatinase inhibitors and use thereof
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
IL246768A0 (en) Benzoquinolone compounds as vmat2 inhibitors
MA47729A (fr) Inhibiteurs de bêta-sécrétase
MA47730A (fr) Inhibiteurs de bêta-sécrétase
MA47731A (fr) Inhibiteurs de bêta-sécrétase
HK1227281A1 (en) Benzoquinoline inhibitors of vesicular monoamine transporter 2
TH1601002537A (th) กระบวนการสำหรับการสังเคราะห์สารยับยั้งอินโดลเอมีน 2,3-ไดออกซีจีเนสชนิดหนึ่ง
TH1501007381A (th) สารต้านแอนโดรเจน/สารยับยั้ง Cyp 17 ชนิดใหม่ (Novel Cyp 17 inhibitors/antiandrogen)